Figure 6: LCK constitutes a potential novel drug target in NSCLC KRAS-Dep cell lines.
From: Reconstructing targetable pathways in lung cancer by integrating diverse omics data
(a) LCK knockdown impairs cell proliferation specifically in KRAS-Dep cell lines. LCK knockdown with two independent shRNAs showed statistically significant reduction in cell proliferation in KRAS-Dep but not KRAS-Ind cell lines (LCK shRNA-1 t-test P-value=0.0001822 and LCK shRNA-3 t-test P-value=4.14 exp−06). Bars correspond to the average of three independent experiments and error bars are defined as s.e.m. (b) Inhibition of LCK using small-molecule inhibitor preferentially impaired cell proliferation in KRAS-Dep but not in KRAS-Ind cell lines. Points represent the average over four independent experiments and error bars are defined as s.e.m.
